REFERENCES
- NICE (National Institute for Health and Clinical Excellence). Long-acting reversible contraception. Clinical Guideline 30. London: RCOG Press 2005. Accessed 26 August 2012 from: www.nice.org.uk/CG030
- Population Council. Bellagio Consensus: Recommendations for action to increase access to highly effective, long-acting, reversible contraception. 2012. Accessed 17 October 2012 from: http://www.popcouncil.org/pdfs/MediaCenter/2012_BellagioRecommendations.pdf.
- Peipert JF, Zhao Q, Allsworth JE, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol 2011;117:1105–13.
- ACOG Committee Opinion no. 450. Increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet Gynecol 2009;114:1434–8.
- Short M, Dallay D, Omokanye S, et al. Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: One-year results of an observational study. Eur J Contracept Reprod Health Care 2012;17:79–88.
- Moreau C, Bouyer J, Bajos N, et al. Frequency of discontinuation of contraceptive use: Results from a French population-based cohort. Hum Reprod 2009;24: 1387–92.
- Croxatto HB, Urbancsek J, Massai R, et al. A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group. Hum Reprod 1999;14:976–81.
- Varney SJ, Guest JF. Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK. Pharmacoeconomics 2004;22:1141–51.
- Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low- dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril 2012;97:616–22.
- Baldaszti E, Wimmer-Puchinger B, Loschke K. Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): A 3-year follow-up study. Contraception 2003;67:87–91.
- Hidalgo M, Bahamondes L, Perrotti M, et al. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 2002;65:129–32.
- Weisberg E, Fraser I. Australian women's experience with Implanon. Aust Fam Physician 2005;34:694–6.
- Suvisaari J, Lahteenmaki P. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system. Contraception 1996; 54:201–8.
- Davie JE, Walling MR, Mansour DJ, et al. Impact of patient counseling on acceptance of the levonorgestrel implant contraceptive in the United Kingdom. Clin Ther 1996;18:150–9.
- Backman T, Huhtala S, Luoto R, et al. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet Gynecol 2002; 99:608–13.
- Haimovich S. Profile of long-acting reversible contraception users in Europe. Eur J Contracept Reprod Health Care 2009;14:187–95.
- Mosher WD, Jones J. Use of contraception in the United States: 1982–2008. Vital Health Stat 23 2010; 29:1–44.